AILatent Space
Ian Quigley, co-founder and CEO of Leash Bio, explains how his company combines DNA-encoded libraries (DELs) and high-throughput sequencing to generate billions of reproducible protein-small-molecule binding measurement…
- A single researcher working in Ian Quigley's basement generated a four-billion-measurement dataset using DNA-encoded chemical libraries. Read →
- Leash Bio trained a classifier on 1,815 prolific chemists in the public ChEMBL database and hit 60% top-five accuracy predicting which scientist built a given molecule. Read →
- Sri Kosuri challenges the machine learning drug discovery model: if training a predictive network requires testing millions of physical molecules, you should simply develop the ph… Read →
AILatent Space
In this panel discussion moderated by Brandon Anderson, Google DeepMind's Pushmeet Kohli and CZ Biohub's Sal Candido discuss whether the 'Bitter Lesson' of AI scaling applies directly to biological data and modeling. Th…
- DeepMind's Pushmeet Kohli argues AlphaFold 2 cannot be interpretable to people because biological mechanisms exceed the cognitive capacity of the human brain. Read →
- Sal Candido warns that scaling laws do not appear automatically in biology; discovering the exact regimes where data volume predictably drives performance is an open empirical pro… Read →
- DeepMind designed AlphaFold 2 by hardcoding biophysical rules into the network rather than relying on pure compute scaling. Read →
AILatent Space
This episode delves into Zera Therapeutics' AI drug discovery platform, focusing on their X-Cell model. Guests Bo Wang and Ci Chu explain how X-Cell leverages high-throughput causal data generation (Perturb-seq) and a n…
- Academic freedom isn't a luxury, it's a speed advantage. Bo Wang argues university labs, free from immediate profit pressures, are the wellspring for radically new concepts, like… Read →
- Even with advanced AI drug discovery platforms like Zera Therapeutics’ X-Cell model, the current bottleneck for virtual cell modeling isn't just compute power or algorithms, but t… Read →
- Zera Therapeutics' X-Cell model uses a diffusion language model architecture to predict cellular responses, departing from traditional auto-regressive (GPT-like) methods. Read →
AILatent Space
This episode explores how Genesis Molecular AI is leveraging advanced AI, particularly diffusion models, to revolutionize drug discovery by achieving unprecedented accuracy in protein-ligand structure prediction. Guests…
- The highest leverage for AI in healthcare isn't identifying new disease targets or optimizing clinical trials; it's in the drug discovery and design process itself. Read →
- The 1 Angstrom Cliff: Genesis Molecular AI's Pearl model demonstrates that for drug discovery, 1 angstrom (Å) resolution isn't just nice-to-have; it's the absolute minimum thresho… Read →
AILatent Space
This episode features Carina Hong, CEO of Axiom Math, discussing her company's vision for formal verification as the foundation for superintelligence and AGI, backed by a significant Series A funding round. Hong details…
- AI, particularly Lean-based systems, struggles with highly creative mathematical domains like combinatorics because the necessary steps are often too intuitive and "quite creative… Read →
- Axiom Math secured a $200 million Series A funding round, valuing the company at $1.6 billion, to advance "verified AI." Read →
- Axiom Math, fresh off a $200 million Series A, aims to move formal verification beyond mere error correction, focusing instead on scaling "brilliance" to achieve superhuman math p… Read →